Brookline Capital Management Comments on YMAB Q1 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Investment analysts at Brookline Capital Management increased their Q1 2025 earnings estimates for shares of Y-mAbs Therapeutics in a report released on Tuesday, March 4th. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($0.17) per share for the quarter, up from their prior forecast of ($0.22). Brookline Capital Management has a "Strong-Buy" rating on the stock. The consensus estimate for Y-mAbs Therapeutics' current full-year earnings is ($0.65) per share. Brookline Capital Management also issued estimates for Y-mAbs Therapeutics' Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.81) EPS.

A number of other research firms also recently commented on YMAB. Wedbush reaffirmed an "outperform" rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Oppenheimer initiated coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They set an "outperform" rating and a $23.00 target price on the stock. Morgan Stanley decreased their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research note on Wednesday, March 5th. Finally, Truist Financial cut their price objective on Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $19.30.

Remove Ads

Y-mAbs Therapeutics Stock Up 3.8 %

Shares of YMAB traded up $0.18 during midday trading on Friday, reaching $4.94. 338,078 shares of the stock were exchanged, compared to its average volume of 467,358. The company has a market cap of $223.38 million, a price-to-earnings ratio of -9.15 and a beta of 0.65. Y-mAbs Therapeutics has a 12-month low of $4.25 and a 12-month high of $17.78. The firm has a 50 day simple moving average of $6.22 and a 200-day simple moving average of $10.38.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $26.50 million for the quarter, compared to analysts' expectations of $26.70 million. During the same quarter in the prior year, the business posted ($0.02) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in YMAB. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter worth $44,000. KLP Kapitalforvaltning AS acquired a new stake in Y-mAbs Therapeutics in the 4th quarter worth $46,000. ProShare Advisors LLC bought a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth about $99,000. Intech Investment Management LLC acquired a new position in shares of Y-mAbs Therapeutics during the third quarter valued at about $133,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock valued at $137,000 after buying an additional 6,131 shares during the period. 70.85% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.